Clinical trial

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

NCT00417079

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention cabazitaxel (XRP6258) (RPR116258) Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record mitoxantrone Normalized identity: mitoxantroneView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record prednisone Normalized identity: prednisoneView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-01-01

PhasePHASE3

Conditions

Neoplasmsunresolved

Prostatic Neoplasmsunresolved

Interventions

cabazitaxel (XRP6258) (RPR116258)DRUG

mitoxantroneDRUG · verified · RxNorm: mitoxantrone

prednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

Sanofilead sponsor

Mapped research locations

SeoulSouth Korea1 BarcelonaSpain1 ParisFrance1 BerlinGermany1 MilanItaly1 TaipeiTaiwan1 MoscowRussia1 BudapestHungary1 PragueCzechia1 IstanbulTurkey (Türkiye)1 Buenos AiresArgentina1 São PauloBrazil1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00417079 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.